AMLX Stock Summary and Trading Ideas (Amylyx Pharmaceuticals | NASDAQ:AMLX)

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.

Amylyx Pharmaceuticals trades on the NASDAQ stock market under the symbol AMLX.

As of May 13, 2024, AMLX stock price climbed to $1.82 with 1,314,424 million shares trading.

AMLX has a beta of 1.94, meaning it tends to be more sensitive to market movements. AMLX has a correlation of 0.02 to the broad based SPY ETF.

AMLX has a market cap of $123.77 million. This is considered a Micro Cap stock.

Last quarter Amylyx Pharmaceuticals reported $89 million in Revenue and -$.12 earnings per share. This fell short of revenue expectation by $-10 million and missed earnings estimates by -$.11.

The top ETF exchange traded funds that AMLX belongs to (by Net Assets): VTI, VB, VBK, IWM, XPH.

AMLX has underperformed the market in the last year with a return of -93.7%, while the SPY ETF gained +27.8%. In the last 3 month period, AMLX fell short of the market, returning -88.7%, while SPY returned +4.3%. However, in the most recent 2 weeks AMLX has outperformed the stock market by returning +3.4%, while SPY returned +2.5%.

AMLX support price is $1.67 and resistance is $1.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMLX stock will trade within this expected range on the day.